

Creo Medical Group plc
("Creo", the "Company" or the "Group")

Capital Markets Day update

CMD to be rearranged to allow clinician case using Creo products to be completed

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that the Company's Capital Markets Day, due to take place on Thursday 9 October, will be rearranged for later in the year as a scheduling conflict has arisen with a keynote speaker who now has a lung tumour ablation case on the same date. Given the significance of this clinician's activity within Creo's clinical programme and, more importantly, the patient's clinical need, the Board have decided to rearrange the Capital Markets Day.

A further announcement relating to the new date and arrangements for the Capital Markets Day will be published in due course.

For further information please contact:

Creo Medical Group plc
Richard Craven, Company Secretary

www.creomedical.com
Via Walbrook PR

Deutsche Numis (Nominated Adviser, Broker and Financial Adviser)
Freddie Barnfield / Duncan Monteith / Sher Shah

+44 (0)20 7260 1000

Walbrook PR Ltd
Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654



About Creo Medical

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFLFVIRLDIIE